Oncostatin M (OSM): A Member of IL-6 Cytokine Family, An Underestimated Player in Future Targeted Therapies?
Oncostatin M (OSM): A Member of IL-6 Cytokine Family, An Underestimated Player in Future Targeted Therapies?Cytokines are molecules produced by immune cells that play a crucial role in regulating the immune response. Some cytokines are pro-inflammatory while others are anti-inflammatory. Numerous inflammation-related cytokines...
Detailed information

CDCP1: A Key Mediator for Cell Signaling in Cancers, an Emerging Target for Anti-Tumor Drugs!
CDCP1: A Key Mediator for Cell Signaling in Cancers, an Emerging Target for Anti-Tumor Drugs!Recently, Nature Communications published a paper entitled "The blood proteome of imminent lung cancer diagnosis". Using a high-throughput proteomics approach, researchers at Harvard Medical School screened blood samples...
Detailed information

IL2RA (CD25): A Specific Marker of Tregs Functions as Both Immune Modulators and Targeted Agents in Various Diseases!
IL2RA (CD25): A Specific Marker of Tregs Functions as Both Immune Modulators and Targeted Agents in Various Diseases!Regulatory T cells (Tregs) are vital in immune control. On Aug 8, 2023, Innovent Biologics company published a article in Nature Cancer regarding "IL-2Rα-biased agonist boosts tumor-fighting CD25+CD8+T cells". The study...
Detailed information

BDCA2/CLEC4C: a Novel Plasma Cell-Like Dendritic Cell (pDC) Marker and Potent Inhibitor of IFN-I that Blocks SLE Development!
BDCA2/CLEC4C: a Novel Plasma Cell-Like Dendritic Cell (pDC) Marker and Potent Inhibitor of IFN-I that Blocks SLE Development!Recently, Rheumatology published a research paper entitled "An immunomodulatory antibody-drug conjugate (ADC) targeting BDCA2 strongly suppresses pDC function and glucocorticoid responsive genes. glucocorticoid responsiv...
Detailed information

GLP-1R: An Energy Metabolism Regulator of GPCR Family, an Effective Drug Target for Type 2 Diabetes Therapy!
GLP-1R: An Energy Metabolism Regulator of GPCR Family, an Effective Drug Target for Type 2 Diabetes Therapy!GLP-1R, a member of the GPCR family B, has become a prominent focus in drug discovery due to its remarkable ability to regulate glucose and energy metabolism. Its pivotal role in managing diabetes and obesity, with benef...
Detailed information

DKK1: a Well-Characterized Wnt Inhibitor, a Multifunctional Regulator in Multiple Cancers!
DKK1: a Well-Characterized Wnt Inhibitor, a Multifunctional Regulator in Multiple Cancers!Recently, DKK1 has garnered attention in tumor therapy due to promising clinical studies. Junshi Biosciences' JS015 injection, a humanized anti-DKK1 monoclonal antibody for advanced malignant solid tumors, received IND a...
Detailed information

CEACAM6: a Potent CEA Family Molecule, a New Tumor Marker or Anti-Cancer Target!
CEACAM6: a Potent CEA Family Molecule, a New Tumor Marker or Anti-Cancer Target!A recent article published in the American Journal of Respiratory and Critical Care Medicine reveals that CEACAM6 is a key inhibitor of HO-1 inhibitor that contributes to the development of lung disease [1]. Carcinoembry...
Detailed information

MYL9: a New Member of Myosin Motors, a Key Driver of Cancer Cell Dynamic Regulation?
MYL9: a New Member of Myosin Motors, a Key Driver of Cancer Cell Dynamic Regulation?MYL9, the regulatory light chain of myosin, is essential for cell movement by activating myosin motility. It has been shown that MYL9 promotes cancer cell migration and is implicated in tumor development and progression....
Detailed information

SIGIRR: A Novel Member of the TIR Superfamily Acts as the Anti-Inflammatory 'Brake' to Control Immune Response in Various Diseases!
SIGIRR: A Novel Member of the TIR Superfamily Acts as the Anti-Inflammatory 'Brake' to Control Immune Response in Various Diseases!Lately, the journal Seminars in Immunology published an intriguing article titled "IL-1R8: A Molecular Brake for Anti-Tumor and Anti-Viral Activity of NK Cells and ILCs" [1]. The study highlights the significance of IL-1...
Detailed information

The Power and Promise of Stable Cell Lines
The Power and Promise of Stable Cell LinesThe HeLa cell line, the first immortalized human cell line, was established in 1951 [1]. In 1975, hybridoma technology enabled the generation of stable hybridoma cell lines producing monoclonal antibodies [2]. Recombinan...
Detailed information

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1